JP2003012486A - Skin care preparation - Google Patents

Skin care preparation

Info

Publication number
JP2003012486A
JP2003012486A JP2001197282A JP2001197282A JP2003012486A JP 2003012486 A JP2003012486 A JP 2003012486A JP 2001197282 A JP2001197282 A JP 2001197282A JP 2001197282 A JP2001197282 A JP 2001197282A JP 2003012486 A JP2003012486 A JP 2003012486A
Authority
JP
Japan
Prior art keywords
ceramide
skin
acid
type
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001197282A
Other languages
Japanese (ja)
Other versions
JP4644391B2 (en
Inventor
Taizo Seki
泰三 関
Hayashi Maeda
速 前田
Yasuyuki Yamamoto
泰之 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP2001197282A priority Critical patent/JP4644391B2/en
Publication of JP2003012486A publication Critical patent/JP2003012486A/en
Application granted granted Critical
Publication of JP4644391B2 publication Critical patent/JP4644391B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a skin care preparation having high solubility of ceramide, excellent stability of the preparation and good transcutaneous absorptivity of ceramide, effectively improving the barrier function of the cuticle layer of the skin and exhibiting excellent skin moisturizing action and protecting action. SOLUTION: The preparation contains a mixture of type II ceramide and type III ceramide in combination with one or more compounds selected from 16-18C branched fatty acids, 10-24C branched aliphatic alcohols and glyceryl monooleyl ether. The fatty acid is selected preferably from 14- methylpentadecanoic acid, 16-methylheptadecanoic acid, 2-heptylundecanoic acid and 2-isoheptylisoundecanoic acid expressed by formula (1) and the aliphatic alcohol is selected preferably from an aliphatic alcohol expressed by formula (2), 2-hexyldecanol, 2-octyldodecanol and 2-decyltetradecanol.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、皮膚のバリア機能
を向上させ、優れた皮膚保湿効果及び皮膚保護効果を発
揮し、小じわやきめの粗さといった皮膚の老化症状を予
防,改善し得る皮膚外用剤に関する。さらに詳しくは、
II型セラミド及びIII型セラミドの混合物を、炭素数1
6〜18の分岐鎖を有する脂肪酸,炭素数10〜24の
分岐鎖を有する脂肪族アルコール,グリセリルモノオレ
イルエーテルより選択した1種又は2種以上とともに含
有して成る皮膚外用剤に関する。
TECHNICAL FIELD The present invention relates to a skin capable of improving the barrier function of the skin, exerting an excellent skin moisturizing effect and a skin protecting effect, and preventing and improving aging symptoms of the skin such as fine wrinkles and roughness of the skin. Regarding external preparations. For more details,
A mixture of type II ceramide and type III ceramide has 1 carbon atom
The present invention relates to a skin external preparation containing one or two or more selected from fatty acids having 6 to 18 branched chains, aliphatic alcohols having 10 to 24 carbon branched chains, and glyceryl monooleyl ether.

【0002】[0002]

【従来の技術】乾燥,紫外線等種々の環境因子や、加齢
に伴う皮膚の老化、アトピー性病変等により、皮膚角質
層のバリアー機能が低下し、肌荒れ症状が生じることが
知られており、皮膚角質層のバリアー機能に関与するセ
ラミドを配合した皮膚外用剤が数多く開示されている。
It is known that the barrier function of the stratum corneum of the skin is lowered due to various environmental factors such as dryness and ultraviolet rays, aging of the skin with aging, atopic lesions, etc. Many external preparations for skin containing ceramide, which is involved in the barrier function of the stratum corneum of the skin, have been disclosed.

【0003】皮膚角質層のバリアー機能を構築するに
は、セラミドがラメラ状に配列される必要があるが、動
物組織より抽出したセラミド混合物を単に皮膚外用剤に
配合しただけでは、かかる配列を得ることはできない。
また、皮膚のセラミドと同一の立体異性体構造を有する
III型セラミドの製法が知られているが、III型セラミド
は融点が高く、皮膚外用剤基剤に溶解することが困難で
ある。
In order to construct the barrier function of the stratum corneum of the skin, ceramides need to be arranged in a lamella shape, but such a arrangement can be obtained by simply blending a ceramide mixture extracted from animal tissue with an external skin preparation. It is not possible.
It also has the same stereoisomeric structure as skin ceramide.
Although a method for producing type III ceramide is known, type III ceramide has a high melting point and is difficult to dissolve in a skin external preparation base.

【0004】III型セラミドの融点を低下させる試みと
しては、V型セラミドと併用する技術が知られている
(特開平8−225427)。しかしながら、より安定
な皮膚外用剤を得るには、皮膚外用剤基剤に対するセラ
ミドの溶解性を向上させる必要があり、皮膚角質層のバ
リアー機能を向上させるためには、セラミドの経皮吸収
性を向上させる必要があった。
As an attempt to lower the melting point of type III ceramide, a technique of using it in combination with type V ceramide is known (Japanese Patent Laid-Open No. 8-225427). However, in order to obtain a more stable skin external preparation, it is necessary to improve the solubility of ceramide in the skin external preparation base, and in order to improve the barrier function of the skin stratum corneum, the transdermal absorbability of ceramide is required. I needed to improve.

【0005】[0005]

【発明が解決しようとする課題】そこで本発明において
は、セラミドの溶解性が良好で製剤安定性に優れ、さら
にセラミドの経皮吸収も良好で、皮膚角質層バリアー機
能を有効に向上させることができ、優れた皮膚の保湿効
果及び保護効果を発揮し得る皮膚外用剤を得ることを目
的とした。
Therefore, in the present invention, the solubility of ceramide is good and the formulation stability is excellent, and the transdermal absorption of ceramide is also good, and it is possible to effectively improve the skin stratum corneum barrier function. The object was to obtain an external preparation for skin which can be produced and can exert an excellent skin moisturizing effect and protective effect.

【0006】[0006]

【課題を解決するための手段】上記課題を解決するべく
種々検討した結果、II型セラミド及びIII型セラミドの
混合物を、炭素数16〜18の分岐鎖を有する脂肪酸,
炭素数10〜24の分岐鎖を有する脂肪族アルコール,
グリセリルモノオレイルエーテルより選択した1種又は
2種以上とともに含有させることにより、皮膚外用剤基
剤に対する溶解性及び経皮吸収性が向上し、優れた皮膚
の保湿効果及び保護効果が得られ、その結果、小じわや
きめの粗さといった皮膚の老化症状の予防,改善にも有
効であることを見いだし、本発明を完成するに至った。
[Means for Solving the Problems] As a result of various studies to solve the above problems, a mixture of a type II ceramide and a type III ceramide was selected from fatty acids having a branched chain having 16 to 18 carbon atoms,
An aliphatic alcohol having a branched chain having 10 to 24 carbon atoms,
By incorporating together with one or more selected from glyceryl monooleyl ether, the solubility and percutaneous absorbability of the skin external preparation base are improved, and excellent skin moisturizing effect and protective effect are obtained. As a result, they have found that they are also effective in preventing and improving skin aging symptoms such as fine wrinkles and roughness of texture, and have completed the present invention.

【0007】[0007]

【発明の実施の形態】本発明において用いるII型セラミ
ドは、N-アシルスフィンゴシン又はN-アシルジヒドロス
フィンゴシンであり、動物等の各組織より抽出,分画し
て得たものや、化学的もしくは酵素的手法により合成さ
れたものを用いることができる。アシル基としては、炭
素数12〜38程度の飽和又は不飽和のものが好まし
く、ヒドロキシル基を有するものでもよい。
BEST MODE FOR CARRYING OUT THE INVENTION The type II ceramide used in the present invention is N-acyl sphingosine or N-acyl dihydrosphingosine, which is obtained by extraction and fractionation from various tissues such as animals, chemical or enzymatic What was synthesize | combined by the dynamic method can be used. The acyl group is preferably a saturated or unsaturated one having about 12 to 38 carbon atoms, and may have a hydroxyl group.

【0008】また、本発明においてII型セラミドととも
に用いるIII型セラミドは、N-アシルフィトスフィンゴ
シンであり、動物,植物,酵母等の各組織より抽出,分
画して得たものや、化学的もしくは酵素的手法により合
成されたものを用いることができる。アシル基として
は、炭素数12〜38程度の飽和又は不飽和のものが好
ましく、ヒドロキシル基を有するものでもよい。
The type III ceramide used together with the type II ceramide in the present invention is N-acyl phytosphingosine, which is obtained by extracting and fractionating from tissues of animals, plants, yeasts, etc., or chemically or What was synthesize | combined by the enzymatic method can be used. The acyl group is preferably a saturated or unsaturated one having about 12 to 38 carbon atoms, and may have a hydroxyl group.

【0009】本発明において用いるII型セラミドとIII
型セラミドとの混合物におけるこれら各セラミドの混合
重量比としては、4:6〜6:4の範囲とするのが適切
である。
Type II ceramide and III used in the present invention
The mixing weight ratio of these ceramides in the mixture with the type ceramide is appropriately in the range of 4: 6 to 6: 4.

【0010】本発明において、II型セラミド及びIII型
セラミドの混合物と併用する炭素数16〜18の分岐鎖
を有する脂肪酸としては、分岐鎖を有する飽和脂肪酸が
好ましく、14-メチルペンタデカン酸,16-メチルヘプタ
デカン酸,2-ヘプチルウンデカン酸及び式(1)で示さ
れる2-イソヘプチルイソウンデカン酸が好ましいものと
して例示され、本発明においてはこれらより1種又は2
種以上を選択して用いる。特に、常温で液状を呈するも
のが好ましく用いられる。
In the present invention, the branched chain fatty acid having 16 to 18 carbon atoms which is used together with the mixture of type II ceramide and type III ceramide is preferably a saturated fatty acid having a branched chain, such as 14-methylpentadecanoic acid, 16- Methylheptadecanoic acid, 2-heptylundecanoic acid and 2-isoheptylisoundecanoic acid represented by the formula (1) are exemplified as preferable ones, and in the present invention, one or two of them are used.
Select and use at least one species. In particular, those that are liquid at room temperature are preferably used.

【化3】 [Chemical 3]

【0011】また本発明において、II型セラミド及びII
I型セラミドの混合物と併用する炭素数10〜24の分
岐鎖を有する脂肪族アルコールとしては、分岐鎖を有す
る飽和の脂肪族アルコールが好ましく、常温で液状を呈
するものが特に好ましく用いられる。式(2)で示され
る脂肪族アルコール,2-ヘキシルデカノール,2-オクチ
ルドデカノール,2-デシルテトラデカノール等が好まし
いものとして例示され、これらより1種又は2種以上を
選択して用いる。
In the present invention, type II ceramide and II
As the aliphatic alcohol having a branched chain having 10 to 24 carbon atoms which is used in combination with the mixture of I-type ceramide, a saturated aliphatic alcohol having a branched chain is preferable, and a liquid alcohol at room temperature is particularly preferably used. Aliphatic alcohols represented by the formula (2), 2-hexyldecanol, 2-octyldodecanol, 2-decyltetradecanol and the like are exemplified as preferable ones, and one kind or two or more kinds are selected and used from these.

【化4】 [Chemical 4]

【0012】さらに本発明においては、II型セラミド及
びIII型セラミドの混合物と、常温で液状を呈するグリ
セリルモノオレイルエーテル(セラキルアルコール)と
を併用することができる。
Further, in the present invention, a mixture of type II ceramide and type III ceramide can be used together with glyceryl monooleyl ether (ceracyl alcohol) which is liquid at room temperature.

【0013】本発明におけるII型セラミド及びIII型セ
ラミドの混合物と、炭素数16〜18の分岐鎖を有する
脂肪酸,炭素数10〜24の分岐鎖を有する脂肪族アル
コール,グリセリルモノオレイルエーテルより選択した
1種又は2種以上との混合重量比としては、0.01:
100〜1:1の範囲とするのが適切である。また、本
発明に係る皮膚外用剤全量に対するII型セラミド及びII
I型セラミドの混合物、及び炭素数16〜18の分岐鎖
を有する脂肪酸,炭素数10〜24の分岐鎖を有する脂
肪族アルコール,グリセリルモノオレイルエーテルより
選択した1種又は2種以上の含有量としては、それぞれ
0.00001〜10.0重量%及び0.1〜20.0
重量%とするのが適切であり、さらに好ましくは、0.
0001〜5.0重量%及び0.5〜10.0重量%と
する。
A mixture of the type II ceramide and the type III ceramide in the present invention, a fatty acid having a branched chain having 16 to 18 carbon atoms, an aliphatic alcohol having a branched chain having 10 to 24 carbon atoms, and glyceryl monooleyl ether are selected. The mixing weight ratio with one or two or more kinds is 0.01:
A range of 100 to 1: 1 is suitable. Further, II type ceramide and II for the total amount of the external preparation for skin according to the present invention
Mixture of I-type ceramide, and fatty acid having a branched chain having 16 to 18 carbon atoms, aliphatic alcohol having a branched chain having 10 to 24 carbon atoms, and one or more kinds selected from glyceryl monooleyl ether Are 0.00001-10.0% by weight and 0.1-20.0%, respectively.
It is suitable that the content is 0.1% by weight, and more preferably 0.
0001 to 5.0% by weight and 0.5 to 10.0% by weight.

【0014】本発明に係る皮膚外用剤は、ローション
剤,乳剤,ゲル剤,クリーム剤,軟膏剤等の形状で提供
することができる。また、化粧水,乳液,ゲル,クリー
ム,パック等の皮膚化粧料、液状もしくはクリーム状の
下地化粧料、液状,クリーム状もしくは油性タイプのフ
ァンデーション,アイカラー,チークカラー等のメイク
アップ化粧料、ハンドローション,ハンドクリーム,レ
ッグクリーム,ネッククリーム,ボディローション等の
身体用化粧料、クレンジングローション,クレンジング
クリーム,クレンジングフォーム等の洗顔料、ボディソ
ープ等の身体用洗浄料、ヘアーシャンプー,ヘアーリン
ス,ヘアーコンディショナー,ヘアークリーム等の毛髪
用化粧料などとして提供され得る。
The external preparation for skin according to the present invention can be provided in the form of lotion, emulsion, gel, cream, ointment and the like. In addition, skin cosmetics such as lotions, emulsions, gels, creams and packs, liquid or creamy base cosmetics, liquid, creamy or oily foundations, make-up cosmetics such as eye color and cheek color, hand Lotion, hand cream, leg cream, neck cream, body lotion and other body cosmetics, cleansing lotion, cleansing cream, cleansing foam and other face wash, body soap and other body wash, hair shampoo, hair conditioner, hair conditioner , And can be provided as a hair cosmetic such as a hair cream.

【0015】なお、本発明に係る皮膚外用剤には、セラ
ミド混合物の溶解性に影響を与えない範囲で、動植物性
油脂類,ロウ類,脂肪酸,脂肪族アルコール,エステル
油類,炭化水素油類といった他の油性成分、界面活性
剤、エタノール等の低級アルコール、多価アルコール,
ピロリドンカルボン酸塩,ムコ多糖類等の保湿剤、乳酸
及びその塩,クエン酸及びその塩等のpH調整剤、水酸
化カリウム,水酸化ナトリウム,L-アルギニン等の塩基
類、酵母抽出物,シルク加水分解物等の細胞賦活剤、ア
スコルビン酸誘導体等の美白剤、トコフェロール及びそ
の誘導体等の抗酸化剤、アラントイン,グリチルレチン
酸及びその誘導体等の抗炎症剤、紫外線防止剤、防菌防
黴剤、香料、色素、顔料、海藻抽出物、各種植物抽出物
等、皮膚外用剤に一般的に配合される成分を含有させる
ことができる。
The external preparation for skin according to the present invention contains animal and vegetable oils and fats, waxes, fatty acids, aliphatic alcohols, ester oils, and hydrocarbon oils as long as the solubility of the ceramide mixture is not affected. Other oily ingredients such as, surfactants, lower alcohols such as ethanol, polyhydric alcohols,
Moisturizers such as pyrrolidone carboxylate and mucopolysaccharides, lactic acid and its salts, pH adjusting agents such as citric acid and its salts, potassium hydroxide, sodium hydroxide, bases such as L-arginine, yeast extract, silk Cell activating agents such as hydrolysates, whitening agents such as ascorbic acid derivatives, antioxidants such as tocopherol and its derivatives, allantoin, anti-inflammatory agents such as glycyrrhetinic acid and its derivatives, UV inhibitors, antifungal agents, Ingredients generally contained in skin external preparations such as fragrances, pigments, pigments, seaweed extracts, and various plant extracts can be contained.

【0016】[0016]

【実施例】さらに本発明の特徴について、実施例により
詳細に説明する。
EXAMPLES The features of the present invention will be described in detail with reference to Examples.

【0017】[実施例1,実施例2] 保湿クリーム 表1に示す処方中、Aの水相成分を混合,加熱溶解して
80〜85℃とする。一方、C成分を混合,加熱溶解し
て80〜85℃とし、これにあらかじめ混合,加熱溶解
して80〜85℃としたB成分を加えて均一とする。こ
の油相成分に前記水相成分を撹拌しながら徐々に添加し
て均一に乳化し、冷却後50℃にてD成分を加え、さら
に35℃まで冷却する。
[Examples 1 and 2] Moisturizing cream In the formulation shown in Table 1, the aqueous phase component A is mixed and heated to 80 to 85 ° C. On the other hand, the C component is mixed and melted by heating to 80 to 85 ° C., and the B component previously mixed and heated and melted at 80 to 85 ° C. is added to make it uniform. The water phase component is gradually added to this oil phase component while stirring to uniformly emulsify, and after cooling, the D component is added at 50 ° C. and further cooled to 35 ° C.

【0018】[0018]

【表1】 [Table 1]

【0019】[実施例3,実施例4] 保湿ジェル 表2に示す処方中、Aの水相成分を混合,加熱溶解して
80〜85℃とする。一方、C成分を混合,加熱溶解し
て80〜85℃とし、これにあらかじめ混合,加熱溶解
して80〜85℃としたB成分を加えて均一とする。こ
の油相成分に前記水相成分を撹拌しながら徐々に添加し
て均一に乳化し、冷却後50℃にてD成分を加え、さら
に35℃まで冷却する。
[Examples 3 and 4] Moisturizing gel In the formulation shown in Table 2, the aqueous phase component A is mixed and heated to 80 to 85 ° C. On the other hand, the C component is mixed and melted by heating to 80 to 85 ° C., and the B component previously mixed and heated and melted at 80 to 85 ° C. is added to make it uniform. The water phase component is gradually added to this oil phase component while stirring to uniformly emulsify, and after cooling, the D component is added at 50 ° C. and further cooled to 35 ° C.

【0020】[0020]

【表2】 [Table 2]

【0021】[実施例5,実施例6] 保湿乳液 表3に示す処方中、Aの水相成分を混合,加熱溶解して
80〜85℃とする。一方、C成分を混合,加熱溶解し
て80〜85℃とし、これにあらかじめ混合,加熱溶解
して80〜85℃としたB成分を加えて均一とする。こ
の油相成分に前記水相成分を撹拌しながら徐々に添加し
て均一に乳化し、冷却後50℃にてD成分及びE成分を
加え、さらに35℃まで冷却する。
[Examples 5 and 6] Moisturizing emulsion In the formulation shown in Table 3, the aqueous phase component A is mixed and heated to 80 to 85 ° C. On the other hand, the C component is mixed and melted by heating to 80 to 85 ° C., and the B component previously mixed and heated and melted at 80 to 85 ° C. is added to make it uniform. The water phase component is gradually added to the oil phase component while stirring to uniformly emulsify, and after cooling, the D component and the E component are added at 50 ° C. and further cooled to 35 ° C.

【0022】[0022]

【表3】 [Table 3]

【0023】[実施例7,実施例8] 保湿ゲル 表4に示す処方中、A成分を混合,溶解して80〜85
℃とする。これに、あらかじめ混合,加熱溶解して80
〜85℃としたB成分及びC成分を加えて混合,均一化
し、冷却する。次いでこれにD成分を混合して徐々に添
加し、撹拌混合してゲルを形成させた後、E成分を添
加,混合する。
[Examples 7 and 8] Moisturizing gel In the formulation shown in Table 4, the component A was mixed and dissolved to obtain 80-85.
℃. To this, mix beforehand and dissolve by heating to 80
Add the components B and C at ˜85 ° C., mix, homogenize, and cool. Next, component D is mixed and gradually added to this, and after stirring and mixing to form a gel, component E is added and mixed.

【0024】[0024]

【表4】 [Table 4]

【0025】上記本発明の実施例について、製剤安定
性,皮膚保湿効果及び皮膚保護効果の評価を行った。そ
の際、各実施例において表5に示すように含有成分の代
替を行ってそれぞれ比較例1〜比較例8とし、同時に試
験に供した。
With respect to the above examples of the present invention, the formulation stability, skin moisturizing effect and skin protective effect were evaluated. At that time, as shown in Table 5 in each Example, the contained components were replaced to obtain Comparative Examples 1 to 8, respectively, which were simultaneously tested.

【0026】[0026]

【表5】 [Table 5]

【0027】製剤安定性については、実施例及び比較例
のそれぞれを25℃で6カ月間保存し、含有成分の析
出,分離,凝集、相分離といった状態変化の有無を観察
し、これらの状態変化が全く見られなかった場合を○、
若干見られた場合を△、顕著に見られた場合を×として
表した。また、皮膚保湿効果及び皮膚保護効果は、顕著
な肌荒れ症状を呈する女性パネラー20名を1群とした
使用試験を行って評価した。すなわち、実施例及び比較
例をそれぞれ各群にブラインドにて1日2回、2カ月間
使用させ、使用試験開始前及び使用試験終了後の角質層
水分量の測定及び皮膚状態の観察を行った。角質層水分
量は、皮表の高周波電気伝導度(コンダクタンス)を測
定し、皮膚表面のコンダクタンス値にて表した。一方皮
膚の状態は、表6に示す評価基準に従って評価,点数化
し、20名の平均値を算出して示した。これらの結果
は、表7にまとめて示した。
Regarding the formulation stability, each of the Examples and Comparative Examples was stored at 25 ° C. for 6 months, and the presence or absence of state changes such as precipitation, separation, aggregation and phase separation of contained components was observed, and these state changes were observed. Is not seen at all, ○,
The case where it was slightly observed was represented by Δ, and the case where it was significantly observed was represented by x. Further, the skin moisturizing effect and the skin protecting effect were evaluated by conducting a use test in which 20 female panelists exhibiting remarkable skin roughening symptoms were used as one group. That is, each of the Examples and Comparative Examples was blindly used twice a day for 2 months, and the water content of the stratum corneum was measured and the skin condition was observed before the start of the use test and after the end of the use test. . The stratum corneum water content was represented by the conductance value of the skin surface by measuring the high frequency electric conductivity (conductance) of the skin surface. On the other hand, the skin condition was evaluated and scored according to the evaluation criteria shown in Table 6, and the average value of 20 persons was calculated and shown. The results are summarized in Table 7.

【0028】[0028]

【表6】 [Table 6]

【0029】[0029]

【表7】 [Table 7]

【0030】表7より明らかなように、本発明の実施例
はすべて良好な製剤安定性を示しており、使用試験にお
いても、全群で皮膚角質層水分量の明らかな向上が認め
られ、皮膚の状態もほぼ良好な状態にまで改善されてい
た。
As is clear from Table 7, all of the examples of the present invention showed good formulation stability, and in the use test, a clear improvement in the skin stratum corneum water content was observed in all groups. The condition was improved to almost good condition.

【0031】これに対し、N-ステアロイルフィトスフィ
ンゴシンをスクワランに代替した比較例4、及びN-パル
ミトイルフィトスフィンゴシンを16-メチルヘプタデカ
ン酸に代替した比較例7以外においては、製剤安定性の
低下が認められていた。また、使用試験終了後の皮膚角
質層水分量及び皮膚の状態は、比較例使用群においても
向上及び改善が見られてはいたが、その程度はそれぞれ
対応する実施例使用群に比べて小さくなっていた。
On the other hand, except for Comparative Example 4 in which N-stearoyl phytosphingosine was replaced with squalane and Comparative Example 7 in which N-palmitoyl phytosphingosine was replaced with 16-methylheptadecanoic acid, the stability of the preparation was decreased. Was admitted. Further, although the skin stratum corneum water content and the skin condition after the use test were improved and improved in the comparative example use group, the degree thereof was smaller than that of the corresponding example use group. Was there.

【0032】なお、本発明の実施例1〜実施例8につい
ては、男性パネラー30名を1群とした48時間の背部
閉塞貼付試験においても、問題となる皮膚刺激性反応は
見られなかった。
Regarding Examples 1 to 8 of the present invention, no problem skin irritation reaction was observed in the 48-hour back-occlusion patch test using 30 male panelists as one group.

【0033】[0033]

【発明の効果】以上詳述したように、本発明により、セ
ラミドの溶解性が良好で製剤安定性に優れ、さらにセラ
ミドの経皮吸収も良好で、皮膚角質層バリアー機能を有
効に向上させることができ、優れた皮膚の保湿効果及び
保護効果を発揮し得る皮膚外用剤を得ることができた。
As described in detail above, according to the present invention, the solubility of ceramide is excellent and the stability of the preparation is excellent, and the percutaneous absorption of ceramide is also good, thereby effectively improving the skin stratum corneum barrier function. Thus, it was possible to obtain an external preparation for skin capable of exerting an excellent skin moisturizing effect and protective effect.

【0034】従って、本発明に係る皮膚外用剤を使用す
ることにより、小じわや皮膚のきめの粗さといった皮膚
の老化症状を有効に予防,改善することができる。
Therefore, by using the external preparation for skin according to the present invention, it is possible to effectively prevent and improve skin aging symptoms such as fine wrinkles and roughness of skin.

フロントページの続き (72)発明者 山本 泰之 滋賀県八日市市岡田町字野上112−1 株 式会社ノエビア滋賀中央研究所内 Fターム(参考) 4C083 AA112 AB032 AC022 AC072 AC091 AC092 AC102 AC122 AC132 AC171 AC242 AC261 AC262 AC422 AC482 AC582 AC641 AC642 AC662 AD042 AD092 AD172 AD192 AD222 AD332 AD352 AD532 CC05 DD31 DD41 EE03 EE12 Continued front page    (72) Inventor Yasuyuki Yamamoto             112-1 Nogami, Okada-cho, Yoka-shi, Shiga             Ceremony Noevir Shiga Central Research Institute F-term (reference) 4C083 AA112 AB032 AC022 AC072                       AC091 AC092 AC102 AC122                       AC132 AC171 AC242 AC261                       AC262 AC422 AC482 AC582                       AC641 AC642 AC662 AD042                       AD092 AD172 AD192 AD222                       AD332 AD352 AD532 CC05                       DD31 DD41 EE03 EE12

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 II型セラミド及びIII型セラミドの混合
物と、炭素数16〜18の分岐鎖を有する脂肪酸,炭素
数10〜24の分岐鎖を有する脂肪族アルコール,グリ
セリルモノオレイルエーテルより選択した1種又は2種
以上を含有して成る、皮膚外用剤。
1. A mixture of type II ceramide and type III ceramide, a fatty acid having a branched chain having 16 to 18 carbon atoms, an aliphatic alcohol having a branched chain having 10 to 24 carbon atoms, and glyceryl monooleyl ether. A skin external preparation containing one or more species.
【請求項2】 II型セラミドが、N-アシルジヒドロスフ
ィンゴシンであることを特徴とする、請求項1に記載の
皮膚外用剤。
2. The external preparation for skin according to claim 1, wherein the type II ceramide is N-acyl dihydrosphingosine.
【請求項3】 III型セラミドが、N-アシルフィトスフ
ィンゴシンであることを特徴とする、請求項1又は請求
項2に記載の皮膚外用剤。
3. The external skin preparation according to claim 1, wherein the type III ceramide is N-acyl phytosphingosine.
【請求項4】 炭素数16〜18の分岐鎖を有する脂肪
酸が、14-メチルペンタデカン酸,16-メチルヘプタデカ
ン酸,2-ヘプチルウンデカン酸及び式(1)で示される
2-イソヘプチルイソウンデカン酸より選択されることを
特徴とする、請求項1〜請求項3に記載の皮膚外用剤。 【化1】
4. The fatty acid having a branched chain having 16 to 18 carbon atoms is represented by 14-methylpentadecanoic acid, 16-methylheptadecanoic acid, 2-heptylundecanoic acid and the formula (1).
The external preparation for skin according to claim 1, which is selected from 2-isoheptylisoundecanoic acid. [Chemical 1]
【請求項5】 炭素数10〜24の分岐鎖を有する脂肪
族アルコールが、式(2)で示される脂肪族アルコー
ル,2-ヘキシルデカノール,2-オクチルドデカノール,
2-デシルテトラデカノールより選択されることを特徴と
する、請求項1〜請求項4に記載の皮膚外用剤。 【化2】
5. The aliphatic alcohol having a branched chain having 10 to 24 carbon atoms is an aliphatic alcohol represented by the formula (2), 2-hexyldecanol, 2-octyldodecanol,
The external preparation for skin according to any one of claims 1 to 4, which is selected from 2-decyltetradecanol. [Chemical 2]
JP2001197282A 2001-06-28 2001-06-28 Skin preparation Expired - Fee Related JP4644391B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001197282A JP4644391B2 (en) 2001-06-28 2001-06-28 Skin preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001197282A JP4644391B2 (en) 2001-06-28 2001-06-28 Skin preparation

Publications (2)

Publication Number Publication Date
JP2003012486A true JP2003012486A (en) 2003-01-15
JP4644391B2 JP4644391B2 (en) 2011-03-02

Family

ID=19034913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001197282A Expired - Fee Related JP4644391B2 (en) 2001-06-28 2001-06-28 Skin preparation

Country Status (1)

Country Link
JP (1) JP4644391B2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006290751A (en) * 2005-04-06 2006-10-26 Kao Corp Oil-in-water type emulsion and method for producing the same
JP2006312622A (en) * 2005-04-06 2006-11-16 Kao Corp Oil-in-water type emulsion and method for producing the same
WO2013022037A1 (en) * 2011-08-09 2013-02-14 花王株式会社 Emulsion composition
JP2013189394A (en) * 2012-03-13 2013-09-26 Tsutsumi Planning:Kk Cosmetic material and cosmetic including the cosmetic material
JP2013543001A (en) * 2010-11-19 2013-11-28 ザ プロクター アンド ギャンブル カンパニー Compositions and methods for improving the appearance of facial pores
JP2014502265A (en) * 2010-11-19 2014-01-30 ザ プロクター アンド ギャンブル カンパニー Methods for improving the appearance of facial texture
WO2015056807A1 (en) 2013-10-17 2015-04-23 Kao Corporation Skin cosmetic composition
WO2015147137A1 (en) * 2014-03-28 2015-10-01 小林製薬株式会社 Ceramide-formulated external agent composition
JP2016088872A (en) * 2014-10-31 2016-05-23 株式会社コスモステクニカルセンター TEXTURE IMPROVING AGENT IN WHICH α GEL-STRUCTURE IS FORMED, AND COSMETIC OR EXTERNAL SKIN PREPARATION FOR IMPROVING TEXTURE CONTAINING THE SAME
US9820925B2 (en) 2014-05-30 2017-11-21 Kao Corporation Skin cosmetic
US10732171B2 (en) 2011-12-20 2020-08-04 The Procter & Gamble Company Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114629A (en) * 1999-10-07 2001-04-24 L'oreal Sa Composition for cosmetic containing at least one kind of cationic surfactant, liquid fatty alcohol and ceramide type compound and method using the composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114629A (en) * 1999-10-07 2001-04-24 L'oreal Sa Composition for cosmetic containing at least one kind of cationic surfactant, liquid fatty alcohol and ceramide type compound and method using the composition

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006312622A (en) * 2005-04-06 2006-11-16 Kao Corp Oil-in-water type emulsion and method for producing the same
JP2006290751A (en) * 2005-04-06 2006-10-26 Kao Corp Oil-in-water type emulsion and method for producing the same
JP2016026228A (en) * 2010-11-19 2016-02-12 ザ プロクター アンド ギャンブルカンパニー Methods for improving appearance of facial texture
JP2013543001A (en) * 2010-11-19 2013-11-28 ザ プロクター アンド ギャンブル カンパニー Compositions and methods for improving the appearance of facial pores
JP2014502265A (en) * 2010-11-19 2014-01-30 ザ プロクター アンド ギャンブル カンパニー Methods for improving the appearance of facial texture
KR101834725B1 (en) * 2010-11-19 2018-03-07 더 프록터 앤드 갬블 캄파니 Methods for improving the appearance of facial skin texture
WO2013022037A1 (en) * 2011-08-09 2013-02-14 花王株式会社 Emulsion composition
JP2013053146A (en) * 2011-08-09 2013-03-21 Kao Corp Emulsion composition
CN103732206A (en) * 2011-08-09 2014-04-16 花王株式会社 Emulsion composition
US9339448B2 (en) 2011-08-09 2016-05-17 Kao Corporation Emulsion composition
US10732171B2 (en) 2011-12-20 2020-08-04 The Procter & Gamble Company Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation
JP2013189394A (en) * 2012-03-13 2013-09-26 Tsutsumi Planning:Kk Cosmetic material and cosmetic including the cosmetic material
US9433567B2 (en) 2013-10-17 2016-09-06 Kao Corporation Skin cosmetic composition
WO2015056807A1 (en) 2013-10-17 2015-04-23 Kao Corporation Skin cosmetic composition
JP2015189723A (en) * 2014-03-28 2015-11-02 小林製薬株式会社 Ceramide-containing external preparation composition
WO2015147137A1 (en) * 2014-03-28 2015-10-01 小林製薬株式会社 Ceramide-formulated external agent composition
US9820925B2 (en) 2014-05-30 2017-11-21 Kao Corporation Skin cosmetic
JP2016088872A (en) * 2014-10-31 2016-05-23 株式会社コスモステクニカルセンター TEXTURE IMPROVING AGENT IN WHICH α GEL-STRUCTURE IS FORMED, AND COSMETIC OR EXTERNAL SKIN PREPARATION FOR IMPROVING TEXTURE CONTAINING THE SAME

Also Published As

Publication number Publication date
JP4644391B2 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
US6120779A (en) Use of partial and complete salts of choline and carboxylic acids for the treatment of skin disorders
HU215488B (en) Method for solubilizing salicylic acid derivatives, cosmetical and/or dermatological compositions containing the solubilized salicylic acid derivatives and use of them
JP2010105980A (en) Cosmetic product containing kudzu starch
JP4644391B2 (en) Skin preparation
JPH11158055A (en) Skin lotion
JPH0657651B2 (en) Cosmetic composition
JP2002161027A (en) Method for suppressing inflammation and erythema and composition therefor
US8097264B2 (en) Natural emulsifying agent
JPH0574566B2 (en)
JP3105345B2 (en) Cosmetics
JP2023553098A (en) Cosmetic composition containing sucrose ester and solvent
JP3568983B2 (en) Hair restorer
JP2023552814A (en) Method for producing cosmetic composition containing sucrose ester and solvent
JP3439871B2 (en) Cosmetics
JP3481775B2 (en) Microemulsions and cosmetics containing them
JP2000344697A (en) Long-chain branched alcohol and cosmetic and external preparation produced by using the alcohol
JP2004010480A (en) Peeling agent for horny layer
JPH07304629A (en) Water-in-oil type emulsion composition and its production
JPH05301814A (en) Cosmetic
JP3382146B2 (en) External preparation for skin
JP3712676B2 (en) External preparation composition
JP2871764B2 (en) Cosmetics
Urata et al. Cholesteryl ester compounds containing alkyl branched acyl groups—their preparations, properties and applications
JPS62413A (en) Cosmetic
JPH08119829A (en) External medicine for skin

Legal Events

Date Code Title Description
RD05 Notification of revocation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7425

Effective date: 20070530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080616

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101206

R150 Certificate of patent or registration of utility model

Ref document number: 4644391

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees